SEC Form 4 · accession 0001179110-17-012520
Blueprint Medicines Corp · BPMC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kate Haviland
Officer — Chief Business Officer
Period of report
Sep 18, 2017
Accepted (ET)
Sep 20, 2017 · 5:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597264
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 18, 2017 | M | 6,356 | $16.28 | A | 6,356 | D | |
| Common StockF3 | Sep 18, 2017 | S | 6,356 | $60.03 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $16.28 | Sep 18, 2017 | M | 6,356 | D | — | Feb 1, 2026 | Common Stock | 6,356 | 107,308 | D |
Explanation of responses
- F1The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 20, 2016 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- F2The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 20, 2016 pursuant to Rule 10b5-1 under the Exchange Act.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.20 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4This option was granted on February 1, 2016. This option vested with respect to 25% of the shares underlying the option on January 5, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter.